Yuhan (South Korea)

Recent papers from Yuhan (South Korea)

1. A multiple ascending dose, phase1b study to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of lesigercept, a long-acting IgETrap-Fc fusion protein, in participants with atopy or allergic diseasesInternational Immunopharmacology · 2026
2. Protective effects of Lactiplantibacillus plantarum YC225 Mixture Are associated with Gut Microbiota in Vulvovaginal Candidiasis.2026
3. Therapeutic Efficacy of YH35324 on FcεRIα-Mediated Mast Cell/Basophil ActivationAllergy Asthma and Immunology Research · 2025
4. Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid LeukemiaCancer Research Communications · 2024
5. Patient Reported Outcomes for SB5, an adalimumab biosIMILAR, in patients with rheumatoid arthritis and ankylosing spondylitis (PRO-SIMILAR): Study protocol for a phase IV, single-arm, open-label trialMedicine Case Reports and Study Protocols · 2024
6. Comparative effectiveness of lazertinib in patients with EGFR T790M-positive non-small-cell lung cancer using a real-world external controlScientific Reports · 2024
7. Abstract 6354: The HER2/4-1BB bispecific antibody, YH32367 (ABL105) demonstrates optimal efficacy and safety for HER2-expressing tumors and exhibits synergistic efficacy when combined with anti-PD-L1Cancer Research · 2024
8. Abstract 2358: YH41723 (IMC-202), a Novel TIGITxPD-L1 bispecific antibody, leads to potent anti-tumor immunity through T cell engaging and T/NK cell activationCancer Research · 2024
9. Lazertinib as a frontline treatment in patients with EGFR-mutated advanced non-small cell lung cancer: Long-term follow-up results from LASER201Lung Cancer · 2024
10. Safety, Tolerability, Pharmacokinetics, and pharmacodynamics of YH35324, a novel Long-Acting High-Affinity IgETrap-Fc protein in subjects with Atopy: Results from the First-in-Human studyInternational Immunopharmacology · 2024
11. Central Nervous System Outcomes of Lazertinib Versus Gefitinib in EGFR-Mutated Advanced NSCLC: A LASER301 Subset AnalysisJournal of Thoracic Oncology · 2023
12. Lazertinib Versus Gefitinib Tyrosine Kinase Inhibitors in Treatment-Naíve Patients With EGFR-Mutated Advanced NSCLC: Analysis of the Asian Subpopulation in LASER301Journal of Thoracic Oncology · 2023
13. Exploration of smart adherence‐monitoring methods in vitamin D‐deficient patients: A pilot feasibility clinical studyClinical and Translational Science · 2023
14. Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non–Small-Cell Lung Cancer: Results From LASER301Journal of Clinical Oncology · 2023
15. Lazertinib versus Gefitinib as First-Line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean SubsetCancer Research and Treatment · 2023
16. Enzyme-derived deer velvet extract activate the immune response in cyclophosphamide-induced immunosuppressive miceFood Science and Biotechnology · 2023
17. Pharmacokinetic properties of a new sustained-release pregabalin tablet in subjects with reduced renal functionTranslational and Clinical Pharmacology · 2023
18. Comparison of the pharmacokinetics and pharmacodynamics of YH4808 in healthy subjects for defining an appropriate dosing regimenTranslational and Clinical Pharmacology · 2021
19. 3D Bacterial flagella as both synthetic biotemplates and ultrathin spacers for enhanced inter-particle coupling and solar energy harvestingMaterials Horizons · 2021
20. Enriching CCL3 in the Tumor Microenvironment Facilitates T cell Responses and Improves the Efficacy of Anti-PD-1 TherapyImmune Network · 2021